drugset / Trial / NCT00882076
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is to establish toxicity and a maximum tolerated dose recommended phase 2 dose of Clofarabine in combination with Etoposide and Mitoxantrone for therapy of relapsed or refractory acute leukemias. The investigators will observe responses with these therapy agents and assess the impact of Clofarabine interacting with Etoposide in induction of DNA strand breaks.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 20 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 8 mg/m2 | — |